UnitedHealth Group Analyst Ratings
Eli Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Comparable A1C Reduction To Daily Insulin Degludec In Phase 3 QWINT-2 Trial; Results Published In NEJM And Presented At EASD 2024; Efsitora Reduced A1C By 1.34% Compared To 1.26% For Insulin Degludec
Global Stocks With the Highest Triple Momentum Analysis – BofA
Here's What the Harris-Trump Debate Means for US Stocks
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Eli Lilly and Co enters a critical period of expanding diet drug production, welcoming a new CFO.
US pharmaceutical giant Eli Lilly and Co. announced that Lucas Montarce, a senior financial expert within the company, has been appointed as the Chief Financial Officer, and the appointment is effective immediately. This personnel change comes at a critical moment as Eli Lilly is investing billions of dollars to expand production to meet the increasing demand for its diabetes and weight loss drugs (such as Mounjaro and Zepbound). Despite FDA approval, Eli Lilly still faces supply shortages.
US Economy Is in 'Middling' Phase as Fed Fights Inflation
Spotlight on AbbVie: Analyzing the Surge in Options Activity
A Glimpse Into The Expert Outlook On Eli Lilly Through 28 Analysts
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $13,000 Today
J&J Rybrevant/Lazcluze Study Shows Superiority Over Tagrisso
CVS, Humana Dip Amid New Mental Health Guidelines, Leerink Note
Unpacking the Latest Options Trading Trends in Danaher
Eli Lilly Analyst Ratings
Oppenheimer Lists Best Stock Ideas Into the 2024 U.S. Elections
Smart Money Is Betting Big In LLY Options
Sector Update: Health Care Stocks Edge Higher Premarket Monday
Amgen Presents New Data For IMDELLTRA In Small Cell Lung Cancer At WCLC 2024; DeLLphi-303 Study Results Show Potential For IMDELLTRA In Combination With A PD-L1 Inhibitor As First-Line Maintenance Therapy In ES-SCLC
Johnson & Johnson Analyst Ratings
Terns Stock Jumps as Weight Loss Drug Succeeds in Early Trial